Tecrea Ltd has been selected for the second cohort of the Accelerating FemTech programme
Tecrea Ltd is proud to announce its selection for the latest cohort of the Accelerating FemTech programme, funded by Innovate UK and the Medical Research Council, and delivered by the Health Innovation Network (HIN) South London in collaboration with partners across...
SOFI 2 South African Partners Visit the UK for Collaborative Initiatives
Tecrea Ltd. is working alongside a South African-based company as part of the Scaling Out for Impact (SOFI 2) program, aimed at advancing UK-South Africa innovation partnerships. This program seeks to accelerate the development and implementation of affordable,...
Tecrea Ltd. Awarded Innovate UK Funding
Tecrea Ltd. has received Innovate UK funding in collaboration with a global veterinary pharmaceutical company to develop a novel therapy for dairy cows that combines tissue release and infection control.Through support from Innovate UK the project will focus on...
Successful Phase 2b human clinical trial result involving Tecrea’s Nanocin technology
A recent Phase 2b human clinical study involving Tecrea's Nanocin technology as part of a novel topical terbinafine antifungal product, has met the primary endpoint (BBTAF202) in patients with onychomycosis, showing superiority over placebo (vehicle) with a high level...
Tecrea Announces Successful Completion of NBIC Flexible Talent Mobility Accounts Award Project
Tecrea Ltd. is thrilled to announce the successful completion of the NBIC FTMA award, which was used for an industry-academia exchange and collaboration with the Bladder Infection and Immunity Group, UCL. This grant has facilitated a fruitful exchange of knowledge and...